Ning Wei, PhD

Research Instructor

Hillman Cancer Center
5117 Centre Avenue Research Pavilion, Lab 2.43
Pittsburgh, PA 15232
Phone: 412-623-3255
Fax: 412-623-7778


BS (Clinical Pharmacy), Jinzhou Medical University, China, 2004

MS (Pharmacology), Liaoning Medical University & Institute of Oceanology, Chinese Academy of Sciences, China, 2007

PhD (Pharmacology), Peking Union Medical College & Chinese Academy of Medical Sciences, China, 2011
Ning Wei, PhD
Dr. Wei’s research is focused on cancer pharmacology and drug discovery. Design and development of small molecular kinase inhibitors and natural products against human colorectal cancer (CRC), includes: sensitizing strategy to improve the efficacy of Kras inhibitor in human CRC; discovery of a novel therapeutic STAT3 inhibitor (BOL), and it can be used either alone or in combination with MEK inhibitors for the treatment of human CRC; identify PKD2 as the dominant isoform expressed in human CRC, small molecule inhibitors (CRT0066101/kb-NB142-70) or PKD2-targeted siRNAs exerts potent antitumor activity and synergistically enhance the cytotoxic effect of regorafenib; discovery of novel natural products from Chinese Herbal Medicine. Approximately 30% of all anticancer drugs used globally are derived from plant and/or animal sources. Following isolation from the Chinese herbs, we have screened and pre-clinical evaluated the antitumor activity of tetrandrine and its derivative H1, podophyllotoxin derivative and quassinoid analogs.

Journal Articles

Wei N, Li J, Fang C, Chang J, Chu E andSchmitz J. Targeting colon cancer with the novel STAT3 inhibitor. Oncogene 38(10):1676-1687, 2019.
Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, et al. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. Plos One 13(8): e0200836, 2018.
Wang Y, Sun H, Xiao Z, Zhang G, Zhang D, Bao X, Li F, Wu S, Gao Y and Wei N. DNA damage and apoptosis induced by a potent orally podophyllotoxin derivative in breast cancer. Cell Communication and Signaling 16(1):52, 2018.
Wei N, Chu E, Wipf P and Schmitz JC. Protein kinase D as a potential chemotherapeutic target for colorectal cancer. Molecular Cancer Therapeutics 13(5):1130-1141, 2014.
Wei N, Liu GT, Chen XG, Liu Q, Wang FP and Sun H. H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. Biochemical Pharmacology 82(11):1593-1603, 2011.